Innovation Passport awarded Alnylam and its hypertension therapy
The company received the Innovation Passport in the UK for zilebesiran, an investigational treatment of hypertension
Read More
Tag: Alnylam
Alnylam’s RNAi therapeutic Oxlumo gets EU green light
Treatment approved to treat primary hyperoxaluria type 1
Read More
UK’s MHRA allows early access to lumasiran for ultra-rare disease
Lumasiran targets primary hyperoxaluria type 1 (PH1), which affects just around 90 people in the UK and one to three individuals per million in Europe
Read More
Alynlam completes EU, US filings for lumasiran
If approved, lumasiran would be the first approved therapeutic treatment option for primary hyperoxaluria type 1
Read More
Sanofi ends option phase of rare disease alliance with Alnylam
Through the agreement Alnylam will advance an additional investigational asset in an undisclosed rare genetic disease.
Read More
NICE rejects NHS funding for Tegsedi, Onpattro
The National Institute for Health and Care Excellence has issued draft guidelines rejecting NHS funding for two therapies that treat the rare inherited condition hereditary transthyretin-related amyliodsis (hATTR).
Read More
Alnylam’s RNA therapy Onpattro bags EU nod
Alnylam’s RNAi therapeutic Onpattro has been approved for use in Europe to treat Hereditary Transthyretin-Mediated (hATTR) Amyloidosis (hATTR amyloidosis) in adults with Stage 1 or Stage 2 polyneuropathy.
Read More
Sanofi, Alnylam file hATTR amyloidosis therapy in the EU
Sanofi Genzyme and Alnylam Pharmaceuticals have submitted a marketing application to the European Medicines Agency for patisiran, an investigational RNAi therapeutic targeting transthyretin for the treatment of adults with hereditary transthyretin-mediated amyloidosis.
Read More
Sanofi, Alnylam’s RNAi therapeutic smashes PhIII targets
An investigational RNAi therapeutic being developed by Sanofi Genzyme and Alnylam Pharmaceuticals has hit targets in a late stage trial involving patients with hereditary ATTR amyloidosis with polyneuropathy.
Read More
Sanofi snaps up Protein Sciences for $650 million
Sanofi is to buy private US vaccines biotech Protein Sciences in a deal valued at up to $750 million, in a move to bolster its vaccines portfolio.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
